Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 12, 2012 - Issue 10
Submit an article Journal homepage
77
Views
4
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Electric fields for the treatment of glioblastoma

Pasquale De Bonis Institute of Neurosurgery, Catholic University School of Medicine, Largo F Vito, 1, Rome 00168, Italy. [email protected]
,
Francesco Doglietto Institute of Neurosurgery, Catholic University School of Medicine, Largo F Vito, 1, Rome 00168, Italy
,
Carmelo Anile Institute of Neurosurgery, Catholic University School of Medicine, Largo F Vito, 1, Rome 00168, Italy
,
Angelo Pompucci Institute of Neurosurgery, Catholic University School of Medicine, Largo F Vito, 1, Rome 00168, Italy
&
Annunziato Mangiola Institute of Neurosurgery, Catholic University School of Medicine, Largo F Vito, 1, Rome 00168, Italy
Pages 1181-1184 | Published online: 09 Jan 2014

References

  • Ballman KV, Buckner JC, Brown PD et al. The relationship between six-month progression-free survival and 12-month overall survival end points for Phase II trials in patients with glioblastoma multiforme. Neuro-oncology 9(1), 29–38 (2007).
  • Lamborn KR, Yung WK, Chang SM et al. North American Brain Tumor Consortium. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-oncology 10(2), 162–170 (2008).
  • Chamberlain MC. Bevacizumab for the treatment of recurrent glioblastoma. Clin. Med. Insights. Oncol. 5, 117–129 (2011).
  • Hou LC, Veeravagu A, Hsu AR, Tse VC. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg. Focus 20(4), E5 (2006).
  • Osoba D, Brada M, Yung WK, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J. Clin. Oncol. 18(7), 1481–1491 (2000).
  • De Bonis P, Anile C, Pompucci A et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. Acta Neurochir. (Wien.) 154(8), 1371–1378 (2012).
  • Barbagallo GM, Jenkinson MD, Brodbelt AR. ‘Recurrent’ glioblastoma multiforme, when should we reoperate? Br. J. Neurosurg. 22(3), 452–455 (2008).
  • Park JK, Hodges T, Arko L et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J. Clin. Oncol. 28(24), 3838–3843 (2010).
  • Nieder C, Grosu AL, Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treat. Rev. 26(6), 397–409 (2000).
  • Kirson ED, Dbalý V, Tovarys F et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc. Natl Acad. Sci. USA 104(24), 10152–10157 (2007).
  • Kirson ED, Gurvich Z, Schneiderman R et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 64(9), 3288–3295 (2004).
  • Kirson ED, Schneiderman RS, Dbalý V et al. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med. Phys. 9, 1 (2009).
  • Stupp R, Wong ET, Kanner AA et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised Phase III trial of a novel treatment modality. Eur. J. Cancer 48(14), 2192–2202 (2012).
  • Franceschi E, Agati R, Brandes AA. End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era. Expert Rev. Anticancer Ther. 11(11), 1713–1717 (2011).
  • Puduvalli VK, Giglio P, Groves MD et al. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro-oncology 10(2), 216–222 (2008).
  • Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 22(1), 133–142 (2004).
  • Weinstein JN, Lurie JD, Tosteson TD et al. Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT) observational cohort. JAMA 296(20), 2451–2459 (2006).
  • Mangiola A, Maira G, De Bonis P et al. Glioblastoma multiforme in the elderly: a therapeutic challenge. J. Neurooncol. 76(2), 159–163 (2006).
  • Lamers LM, Stupp R, van den Bent MJ et al.; EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cost–effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cancer 112(6), 1337–1344 (2008).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.